Literature DB >> 6198281

Analysis of antigenicity of Clostridium botulinum type C1 and D toxins by polyclonal and monoclonal antibodies.

K Oguma, S Murayama, B Syuto, H Iida, S Kubo.   

Abstract

Clostridium botulinum type C1 toxin was purified from C-Stockholm (C-ST), and D toxin was purified from D-1873 and D-South African. Polyclonal antibodies against these toxins were prepared in rabbits. Twenty-eight monoclonal antibodies to these toxins were also prepared with BALB/c myeloma cells. The antibodies were analyzed by both enzyme-linked immunosorbent assay (ELISA) and a toxin neutralization test. ELISA was performed with the three purified toxins and heavy-chain (Hc) and light-chain (Lc) components derived from C-ST and D-1873 toxins. A neutralization test was carried out with 11 toxin preparations (7 from type C and 4 from type D cultures). ELISA results indicated that there exists at least one common antigenic determinant on each of the Hc and Lc components of the three purified toxins. The results of the neutralization test also indicated that type C1 and D toxin preparations contain several common antigenic sites in their molecules. Some are common to toxins from several specific cultures, whereas others are common to toxins from a large number of cultures. It was speculated that toxins from two type C strains are composed of Hc and Lc components which are somewhat similar to those of D-1873 and C-ST toxins, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198281      PMCID: PMC264338          DOI: 10.1128/iai.43.2.584-588.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties.

Authors:  S Miyazaki; M Iwasaki; G Sakaguchi
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  The toxic antigenic factors produced by Clostridium botulinum types C and D.

Authors:  B C Jansen
Journal:  Onderstepoort J Vet Res       Date:  1971-06       Impact factor: 1.792

4.  Four different monoclonal antibodies against type C1 toxin of Clostridium botulinum.

Authors:  K Oguma; T Agui; B Syuto; K Kimura; H Iida; S Kubo
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

5.  Purification and characterization of two components of botulinum C2 toxin.

Authors:  I Ohishi; M Iwasaki; G Sakaguchi
Journal:  Infect Immun       Date:  1980-12       Impact factor: 3.441

6.  Isolation and molecular size of Clostridium botulinum type C toxin.

Authors:  B Syuto; S Kubo
Journal:  Appl Environ Microbiol       Date:  1977-02       Impact factor: 4.792

7.  Lethal and vascular permeability activities of botulinum C2 toxin induced by separate injections of the two toxin components.

Authors:  I Ohishi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Antigenicity of converting phages obtained from Clostridium botulinum types C and D.

Authors:  K Oguma; H Iida; M Shiozaki; K Inoue
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

9.  Homogeneity and heterogeneity of toxins produced by Clostridium botulinum type C and D strains.

Authors:  K Oguma; B Syuto; T Agui; H Iida; S Kubo
Journal:  Infect Immun       Date:  1981-11       Impact factor: 3.441

10.  Separation and characterization of heavy and light chains from Clostridium botulinum type C toxin and their reconstitution.

Authors:  B Syuto; S Kubo
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

View more
  11 in total

1.  Molecular diversity of neurotoxins from Clostridium botulinum type D strains.

Authors:  K Moriishi; B Syuto; S Kubo; K Oguma
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

Review 2.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

3.  Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin.

Authors:  K Tsuzuki; N Yokosawa; B Syuto; I Ohishi; N Fujii; K Kimura; K Oguma
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

4.  Biochemical classification of Clostridium botulinum type C and D strains and their nontoxigenic derivatives.

Authors:  K Oguma; T Yamaguchi; K Sudou; N Yokosawa; Y Fujikawa
Journal:  Appl Environ Microbiol       Date:  1986-02       Impact factor: 4.792

5.  Purification and characterization of neurotoxin produced by Clostridium botulinum type C 6813.

Authors:  J Terajima; B Syuto; J O Ochanda; S Kubo
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

6.  Binding of Clostridium botulinum type C neurotoxin to different neuroblastoma cell lines.

Authors:  N Yokosawa; Y Kurokawa; K Tsuzuki; B Syuto; N Fujii; K Kimura; K Oguma
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

Review 7.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

8.  Characterization of bacteriophage nucleic acids obtained from Clostridium botulinum types C and D.

Authors:  N Fujii; K Oguma; N Yokosawa; K Kimura; K Tsuzuki
Journal:  Appl Environ Microbiol       Date:  1988-01       Impact factor: 4.792

9.  Molecular cloning of the gene encoding the mosaic neurotoxin, composed of parts of botulinum neurotoxin types C1 and D, and PCR detection of this gene from Clostridium botulinum type C organisms.

Authors:  K Moriishi; M Koura; N Fujii; Y Fujinaga; K Inoue; B Syuto; K Oguma
Journal:  Appl Environ Microbiol       Date:  1996-02       Impact factor: 4.792

Review 10.  Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.

Authors:  Laura M Zarebski; Kerrie Vaughan; John Sidney; Bjoern Peters; Howard Grey; Kim D Janda; Arturo Casadevall; Alessandro Sette
Journal:  Expert Rev Vaccines       Date:  2008-02       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.